<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>School of Biological Sciences</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/75DCBDE0-2625-4A5B-9CAE-4D6DCEE80577"><gtr:id>75DCBDE0-2625-4A5B-9CAE-4D6DCEE80577</gtr:id><gtr:firstName>Joern</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Werner</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD005000%2F1"><gtr:id>F16926F5-D81D-447B-B79D-969790A15063</gtr:id><gtr:title>Structure and mechanism of a novel HIV assembly inhibitor</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D005000/1</gtr:grantReference><gtr:abstractText>In many cases the correct assembly of multiple proteins is critical for their biological function. By interfering specifically with certain protein-protein interactions one can control the assembly and as a result their function. The proteins that encapsulate the genetic information of the HIV virus undergo structural changes that change their arrangement from a spherical to a conical macromolecular assembly. The virus is only infections if the conical assembly is obtained. However, the protein-protein interactions that determine the spherical and the conical assemblies are not well understood. Several models for the arrangement have been proposed that are compatible with range of structural and biochemical data. We have a new small peptide that can interfere with both the spherical and conical assembly of the proteins in a yet unknown way. We are proposing to determine the interaction and the mechanism by which this peptide interferes with the formation of the assemblies. We intend to determine if the inhibitor simply blocks one or more important interfaces that are required for the assembly or whether it induces a conformational change or rearrangement in the protein such that assembly is disrupted. In addition we will determine the interaction of novel classes of molecules that have the same function. This will tell us if the mode of interaction of the inhibitor in hand is unique or if there are several solutions to the assembly inhibition. This will help us to understand the structural determinants that are required for the assembly and correct function of the HIV virus.</gtr:abstractText><gtr:technicalSummary>Assembly of HIV involves trafficking of the structural precursor protein Gag to the plasma membrane, where Gag proteins accumulate and initiate a budding structure. The virus is initially released as an immature, non-infectious particle containing a spherical shell of about 5000 Gag proteins underneath the viral membrane. After release, maturation is initiated by processing of Gag proteins by the viral protease. Five sequential cleavage steps of Gag lead to the separation of the matrix (MA), capsid (CA), nucleocapsid (NC) and p6 proteins as well as two intervening linker regions SP1 and SP2. Complete maturation is only possible after the very last processing step separating CA from the C-terminal 14 residue spacer peptide SP1. The cleavage steps lead to drastic morphological changes inside the virion that are required for viral infectivity. In the mature virus particle only MA remains in a spherical layer attached to the membrane, while CA forms the characteristic conical core that encases the NC-RNA complex. The interactions driving assembly and maturation are still poorly understood. The interactions in the immature (spherical) state are not known. Analysis of in vitro assembled tubular particles as well as those of viral cones in combination with structures of single CA domains shed light on the interactions in the mature capsid, According to these data CA seems to be organized in hexameric rings based on interactions mediated by the N-terminal domain, and each hexamer is connected to six adjacent hexamers via a dimer interface of the C-terminal domain. The C-terminal domain of CA (C-CA) has a hometypic interaction in the crystal structure as well as in solution. In the mature core an additional heterotypic interaction exists between the N- and C-terminal domains of different capsid proteins. However, the current data are compatible with different arrangements of the N- and C-terminal domains of CA. Recently a new peptide was discovered that prevents formation of immature and mature particles in vitro. This provides a new tool to investigate interaction sites and mechanisms that are important for assembly. High resolution nuclear magnetic resonance (NMR) will be used to determine the structure, interaction and mechanism of inhibition of assembly using this novel HIV assembly inhibitor. We will determine the structure of the C-terminal domain of the capsid protein (C-CA) in complex this novel inhibitor and determine the structural and dynamic consequences of inhibitor binding to C-CA on larger Gag constructs, including the multi-domain mature capsid protein and the uncleaved C-CA NC fragment of Gag. We will optimise the peptide ligands and determine the thermodynamics of binding with C-CA (and/or the larger Gag constructs) We will determine the interaction of small molecule inhibitors with C-CA or with larger Gag fragments in order to determine if the mechanism of inhibition is unique to the peptide.</gtr:technicalSummary><gtr:fund><gtr:end>2010-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>236986</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel peptide derived inhibitor of HIV-1 assembly</gtr:description><gtr:id>E18CB931-E8EA-4A32-81F4-5A581F6F33AA</gtr:id><gtr:outcomeId>b961fde6b961fdfa-1</gtr:outcomeId><gtr:piContribution>New collaboration: The Tavasoli group has an interest in HIV inhibitors and a novel technology for creating inhibitors. Werner group has unique methodology to characterise targe inhibitor interaction.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cologne talk 2008</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3C9B220-BAC4-4468-8D80-AB181B860BD0</gtr:id><gtr:impact>discussion, networking, collaboration

new research collaboration</gtr:impact><gtr:outcomeId>5464bd984be635.86286177</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leipzig 2008</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>843EC0B0-27BA-4EB4-8B35-CDBE176607F9</gtr:id><gtr:impact>discussion, networking, collaboration, exchange of materials

not determined</gtr:impact><gtr:outcomeId>5464bdef86ad96.87067660</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSK Visit 2010</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4D1C252B-2D37-4FF9-ACFD-582E14CF1264</gtr:id><gtr:impact>discussion

not determined</gtr:impact><gtr:outcomeId>5464c011ad8682.03694757</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Opening of Soton Diffraction Centre</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EBEED62-1C8A-4D70-B6C5-D74BF584FFCA</gtr:id><gtr:impact>networking

industrial research contract</gtr:impact><gtr:outcomeId>5464c267ae2c71.50519965</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>INSTRUCT 2008</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>67B532A1-96DD-4810-86D7-D988DF12674F</gtr:id><gtr:impact>policy making

formulating research strategy</gtr:impact><gtr:outcomeId>5464bd412425b3.71532380</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Science Week 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>23198048-A2AE-40D3-898E-63D681441B8C</gtr:id><gtr:impact>enthused paraticipants

not measurable by me</gtr:impact><gtr:outcomeId>5464b5ef881eb8.69417962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Science Week 2014</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>18EDF21F-461F-407D-BE97-E712873E9E20</gtr:id><gtr:impact>enthused participants

not measurable by me</gtr:impact><gtr:outcomeId>5464b64124c861.41313304</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chemistry NMR OpenDay</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C691EC84-6500-4BDF-ACB2-5AFEF0DAE2D8</gtr:id><gtr:impact>applications for research projects

not determined</gtr:impact><gtr:outcomeId>5464c346396ec1.06060480</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Science Week 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>382AB250-5D16-4DF0-A36C-A93F13982D2E</gtr:id><gtr:impact>enthused participants

not measurable by me</gtr:impact><gtr:outcomeId>5464b5795da0c9.87009133</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Novel peptide derived inhibitor of HIV-1 assembly</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D68B907-DC66-460D-9CCA-54441BB8E7F9</gtr:id><gtr:impact>General press report Article on the internet

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-690014251.21912190cd8a712</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>Pre-2006,2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SWSBC 2006</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>98D5F3E3-3864-4D73-BF88-874BCFFE85FC</gtr:id><gtr:impact>exchange of ideas

not determined</gtr:impact><gtr:outcomeId>5464ba1d0c0a81.53444919</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>32000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Industry</gtr:description><gtr:end>2006-06-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>456D49B1-FB9C-4CBA-8EB3-296C09A90B55</gtr:id><gtr:outcomeId>5464af546e8806.90824575</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>77000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT funding NMR centre</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A3D24EE7-B704-4B1C-9B21-91DDF28AB331</gtr:id><gtr:outcomeId>5464aea552fbf1.12471483</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT eEF2K</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8ED768FE-D19E-4634-A832-CC23F8908B21</gtr:id><gtr:outcomeId>5464aefe106527.81673381</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Informed the design of novel HIV assembly inhibitors</gtr:description><gtr:id>9F4CECBA-BF00-47F2-8CC2-BBD8DBC81F2D</gtr:id><gtr:impactTypes/><gtr:outcomeId>5464ccca7afaa9.88898246</gtr:outcomeId></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>HIV virus assembly presents a potential target for novel anit AIDS therapies. The molecular mechanisms of the assembly process and how to inhibit it are poorly understood. We found a novel inhibitor for the in-vitro assmbly of HIV virus like particels and characterised its mechanism of assembly inhibition. Novel deriviatives of this inhibitor were developped and new unexpected HIV self interactions controling assembly were discovered.</gtr:description><gtr:exploitationPathways>Perturbing protein protein interactions is of great medical interest, but we currently we do not understand how to control these interactions at the molecular level. The characterisation of this particular protein-protein interaction using also a novel inhibitor provides valuable insight and tools in protein reseach. Having obtained and characterised an inhibitor it is now possible to develop essays for screening large collections of small organic compounds with the aim to find a molecule that is capable of inhibiting the interaction of interest and also is suitable as a lead in a drug development project.</gtr:exploitationPathways><gtr:id>D4031C0B-43A3-4ED2-8A33-B705508C644E</gtr:id><gtr:outcomeId>r-8420191945.8994577772bf48</gtr:outcomeId><gtr:sectors><gtr:sector>Digital/Communication/Information Technologies (including Software),Environment,Manufacturing/ including Industrial Biotechology,Culture/ Heritage/ Museums and Collections,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/D005000/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>